Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab (CNTO 1275) in Active Crohn's Disease
NCT00265122Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2004
- Primary completion
- Nov 2005
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of ustekinumab in Crohn's disease, sponsored by Janssen Pharmaceutical. Started Apr 2004; status: completed.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00265122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00265122.